The Targeted Agent Profiling and Utilization Registry (TAPUR™) Study is designed to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about potential additional uses of these drugs outside of Food and Drug Administration (FDA) approved indications. It provides a clinical trial opportunity for patients with advanced cancer with tumors that have genomic alterations that can be targeted with a TAPUR Study drug. TAPUR is sponsored by the American Society of Clinical Oncology (ASCO), which represents nearly 45,000 oncology professionals around the world who care for people living with cancer. ASCO works to conquer cancer through research, education, and promotion of the highest quality and equitable patient care.
The TAPUR Study is available in a number of largely urban community-based oncology practices, and with this collaboration, JAX enables Maine and New Hampshire to join the TAPUR Study as the first rural states in the Northeast at a statewide level. The TAPUR Study is now enrolling patients at the following locations as part of MCGI: